Patients, n | 177 |
---|---|
Age, years | 68.3 (48–89) |
Prebiopsy prostate-specific antigen level, ng/mL | 10.9 (1.65–218) |
Prostate volume, mL | 42.4 (11–134) |
Positive digital rectal examination result, % | 51 (28.8) |
Systematic cores per prostate, n | 18.4 ± 2.1 |
Targeted cores per prostate, n | 3.84 ± 0.4 |
Patients without prior biopsy, n | 145 |
Patients with prior biopsy negative for cancer, n | 31 |
Patients under active surveillance, n | 1 |
Previous prostate-related treatment, n | 0 |
Gleason score, n | |
6 (3 + 3) | 19 |
7 (3 + 4) | 16 |
7 (4 + 3) | 14 |
8 (4 + 4) | 48 |
≥ 9 (4 + 5, 5 + 4, or 5 + 5) | 19 |
Clinically significant prostate cancer, % | 112 (63.3) |